Company / Depreciation & Amortization
Spyre Therapeutics, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
-
FY2025
5-year range
$0 / $1.6M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
#168 of 168
Health Care
What the data says
Improved from $744,000 to $0 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 0% in Health CareTop 0% of 168
▼
Key checks
Key Insights
- Peak depreciation & amortization was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0 | - |
| FY2024 | $0 | -100.0% |
| FY2023 | $744.0K | -25.3% |
| FY2022 | $996.0K | -36.8% |
| FY2021 | $1.6M | +437.9% |
| FY2020 | $293.0K | +17.7% |
| FY2019 | $249.0K | +88.6% |
| FY2018 | $132.0K | -47.0% |
| FY2017 | $249.0K | +88.6% |
| FY2016 | $132.0K | +48.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026